SCHEMBL3242877

SCHEMBL3242877

CC(=O)Oc1ccc2ccccc2c1[C]=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCEH1 Q6PIU2 10/20 0.48
HTT P42858 4/20 0.46
NPSR1 Q6W5P4 3/20 0.46
GAA P10253 2/20 0.46
GPR55 Q9Y2T6 1/20 0.46
SLC22A6 Q4U2R8 1/20 0.44
LMNA P02545 4/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
RECQL P46063 1/20 0.42
ALDH1A1 P00352 2/20 0.41
PTGS1 P23219 2/20 0.41
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ESR1 P03372 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7912820 0.86 NCEH1 (0.47) NCEH1HTTNPSR1GAAGPR55
SCHEMBL30710587 0.80 MAPT (0.58) NCEH1HTTNPSR1GAAGPR55
SCHEMBL12199931 0.80 MAPT (0.58) NCEH1HTTNPSR1GAAGPR55
SCHEMBL10334136 0.80 NCEH1 (0.71) NCEH1HTTNPSR1GAAGPR55
SCHEMBL3081463 0.80 MAPT (0.58) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL11536584 0.79 NCEH1 (0.49) NCEH1HTTNPSR1GAAGPR55
SCHEMBL6142391 0.78 NCEH1 (0.51) NCEH1HTTNPSR1GAAGPR55
SCHEMBL9683874 0.78 NCEH1 (0.51) NCEH1HTTNPSR1GAAGPR55
SCHEMBL9488962 0.78 HTT (0.54) NCEH1HTTNPSR1GAAGPR55
SCHEMBL23930399 0.77 NCEH1 (0.72) NCEH1HTTNPSR1GAAGPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015109451-A1 SYNTHESIS OF COMPOUNDS CONTAINING 8-OXA-3-AZABICYCLO (3.2.1)OCTANE RING RHODIA OPERATIONS (FR) 2015-07-30 WO disclosed
EP-1167366-B1 AMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2010-05-05 EP disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed
US-3975532-A ANALGESIC ICI UNITED STATES INC. (US) 1976-08-17 US disclosed
US-3953596-A 8-Oxa-3-azabicyclo(3.2.1)octane analgesic compositions and method of alleviating pain in animals ICI UNITED STATES INC. (US) 1976-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 NCEH1 237/4885HTT 3024/4885NPSR1 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.